At Galderma, healthy skin begins with science.
Galderma has an outstanding reputation within the dermatology community for its commitment to the research and development of new dermatological solutions. The skin conditions we treat can have strong psychological and social implications in the everyday lives of our patients. Innovative products like those developed by Galderma help people improve their quality of life.
Sophia-Antipolis, investing in forward-looking R&D technology
Galderma's main R&D centre is located in southeast France, one of Europe's fore-most science and technology hubs. A staff of 450 work at the centre which hosts Galderma's in-house research, pre-clinical and core development activities.
This new 19.300-sq. meter state-of-the-art facility positions Galderma as the world's leading investor in dermatology R&D and underpins its commitment to driving the future of dermatology.
Dedicated R&D centres for the American and Japanese markets
To closely address market needs, Galderma also conducts development in the United States and Japan.
Located in New Jersey, USA, Galderma's Princeton centre specializes in clinical development of products mainly for the North and Latin American markets.
The Tokyo facility focuses on clinical development and regulatory activities specifically for the Japanese market.
Key R&D figures
- 3 R&D centres
- 14.1% of sales
- 320 inventions
- 1,600 publications
- 450 employees in R&D
- 1,750 product registrations
- 4000 patents
At Galderma, healthy skin begins with science.
Galderma has an outstanding reputation within the dermatology community for its commitment to the research and development of new dermatological solutions. The skin conditions we treat can have strong psychological and social implications in the everyday lives of our patients. Innovative products like those developed by Galderma help people improve their quality of life.
Sophia-Antipolis, investing in forward-looking R&D technology
Galderma's main R&D centre is located in southeast France, one of Europe's fore-most science and technology hubs. A staff of 450 work at the centre which hosts Galderma's in-house research, pre-clinical and core development activities.
This new 19.300-sq. meter state-of-the-art facility positions Galderma as the world's leading investor in dermatology R&D and underpins its commitment to driving the future of dermatology.
Dedicated R&D centres for the American and Japanese markets
To closely address market needs, Galderma also conducts development in the United States and Japan.
Located in New Jersey, USA, Galderma's Princeton centre specializes in clinical development of products mainly for the North and Latin American markets.
The Tokyo facility focuses on clinical development and regulatory activities specifically for the Japanese market.
Key R&D figures
- 3 R&D centres
- 14.1% of sales
- 320 inventions
- 1,600 publications
- 450 employees in R&D
- 1,750 product registrations
- 4000 patents